Makena Active Ingredient Compounding Ban Gets US FDA Panel Nod

 
• By Sue Sutter
  
Sunset
The sun is quickly setting on compounding of HPC for preterm birth prevention. (Shutterstock)

More from US Advisory Committees

More from Pathways & Standards